Northstrive advances to Phase III of AI-driven drug discovery program

NorthStrive Biosciences announced the initiation of Phase III of its AI Development Program with Yuva Biosciences under the Development and License Agreement between the parties. Phase III will advance AI-driven compound identification in Phase II of the AI Development Program to experimental validation, marking a significant step towards advancing NorthStrive Biosciences’ pipeline of therapies addressing obesity and related metabolic conditions. Phase III is intended to build on the results of Phase II, in which YuvaBio used its proprietary mitochondrial science-focused artificial intelligence platform, MitoNova, to identify a shortlist of small-molecule candidates, prioritized through computational screening, with potential to promote mitochondrial health and support muscle preservation. This is a concern of growing importance in obesity treatment, particularly for patients using GLP-1 receptor agonists. YuvaBio will now begin generating biological data on these AI-selected compounds, including cytotoxicity screening and ANT1 expression testing at multiple timepoints. Phase III is expected to take approximately 6 to 9 weeks.